Neeta Pradhan, MSc

CRS:

BJMC

Role:

Laboratory

Position:

TB Laboratory Coordinator

Email:

neetapradhanpune@gmail.com

Neeta Pradhan is TB Laboratory Coordinator at the BJGMC-CRS in Pune, India. She has worked as Laboratory Manager at Golwilkar Metropolis Health Services where she was responsible for technical and quality aspects of laboratory testing.

She worked as a Laboratory Coordinator at NARI (National AIDS Research Institute) Clinical Trial Unit for various NIH-funded clinical stuies in the HIV Prevention Trials Network (HPTN), the AIDS Clinical Trial Group (ACTG), and the Microbicide Trial Network (MTN). She was responsible for lab quality management, administration, monitoring and supervision, and coordination and communication as well as additional institutional responsibilities such as lab accreditation.

She has also handled CONDRAD (ICMR) project in the capacity of a Laboratory Coordinator at NARI. She is a NABL (National Accreditation Board for Testing & Calibration of laboratory) 15189 trained internal auditor as well as being trained at GCLP by PPD.

She completed her post graduation at BJGMC, which is affiliated with the University of Pune.

  • Voting Member, Laboratory Technologist Committee (Dec 2017-Nov 2019)
  • Member, TB Laboratory Core Team

Categories

Leadership Committees
CRS
Roles

Clinical Trials

A5342: Evaluating the Safety, Tolerability, and Effect of a...

The purpose of this study is to evaluate the safety, tolerability, and effect of an experimental human monoclonal antibody...

Read More

NWCS 408: Examining Longitudinal Cytokine Profiles in HIV-TB...

Using existing data from A5274 and data obtained from retrospectively testing available biospecimens, we propose the following...

Read More

P2010: Phase III Study of the Virologic Efficacy and Safety...

IMPAACT 2010 is a Phase III, three-arm, randomized, open-label study of HIV-1-infected pregnant women initiating either a...

Read More

A5332: Randomized Trial to Prevent Vascular Events in HIV...

REPRIEVE (A5332) is a large double-blind, randomized, placebo-controlled study of pitavastatin or placebo for about 72 months....

Read More

A5279, Phase III Clinical Trial of Ultra-Short-Course...

This study will enroll HIV-infected people who do not have evidence of active TB but who are at high risk of developing active...

Read More